Breast Cancer

Early-Stage Breast Cancer Clinical Trials

Join Our Clinical Trial: Exploring New Treatments for Early-Stage Breast Cancer

Why This Study Matters

Breast cancer remains one of the most commonly diagnosed cancers globally, with many patients diagnosed at an early stage. For those with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer, standard treatment typically involves endocrine therapy (ET) for 5 to 10 years, using medications like tamoxifen or aromatase inhibitors. This study aims to find out if a new treatment, imlunestrant, is more effective than the current standard ET in reducing the risk of cancer returning.

Goals of the Study

  • Effectiveness: To compare how well imlunestrant (Arm A) works against the current standard of care endocrine therapy (Arm R) in patients who have already received 2 to 5 years of standard ET.
  • Safety: To evaluate the safety and tolerability of each treatment option.

Who Can Participate?

We are looking for participants who:

  • Are 18 years or older.
  • Have been diagnosed with ER+, HER2- early-stage, resected, invasive breast cancer, with no signs of the cancer spreading to other parts of the body.
  • Have completed definitive local-regional therapy.
  • Have received between 24 and 60 months (± 90 days) of any adjuvant ET.

Who Cannot Participate?

You cannot join the study if you:

  • Have evidence of metastatic disease or inflammatory breast cancer at the initial diagnosis.
  • Are pregnant, breastfeeding, or planning to conceive during the study period.
  • Have a history of any other cancer, except for non-melanoma skin cancer, Stage I uterine cancer, or carcinoma in situ of the cervix or other in-situ cancers.
  • Have a serious heart condition.

Interested in Joining?

If you meet the criteria and are interested in contributing to breast cancer research, please consider joining our study. Your participation could improve outcomes for patients with early-stage breast cancer.

For more information and to see if you qualify, please fill out the online eligibility form.

Eligibility Checker:

By clicking submit, you are confirming that you have read & understood the Privacy Policy